Vaccine news gives U.S. value stocks their big day

  • By Saqib Iqbal Ahmed,
  • Reuters
  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

Value stocks notched their best one-day performance against their growth-focused peers ever, by one measure, after Monday’s news of an effective vaccine against the coronavirus sent investors into shares of companies expected to benefit the most from an economic recovery.

Pfizer Inc (PFE) said on Monday its experimental COVID-19 vaccine was more than 90% effective, a potentially major victory in the fight against a pandemic that has killed more than a million people, hammered the world’s economy and upended daily life.

Shares of companies that have struggled for months under coronavirus-fueled lockdowns surged, with the S&P 500 index (.SPX) closing just shy of a record, and some investors believe the moves may have further to run if the vaccine news continues to be favorable.

Value stocks tend to be companies that are more sensitive to the economy’s fluctuations.

Here’s a look at today’s market action, as well as how value and growth have stacked up through the years.

Monday's percentage gain for the Russell 1000 Value Index (.RLV) exceeded that of the Russell 1000 Growth Index (.RLG) by 7.48%, the largest margin in history, driven by bets that the prospects of a working vaccine some time in the next few months could help industries that have suffered under coronavirus lockdowns and travel restrictions.

Sectors such as energy, travel and financials, which were among the hardest hit by lockdowns aimed at curbing the virus, were some of the biggest percentage gainers on Monday, while technology stocks and other “stay-at-home” plays made smaller gains or declined.

Monday’s action stood in contrast to the performance of growth against value over the last several years, when big technology and communications companies have soared while energy and other value sectors have relatively subdued.

  • Facebook.
  • Twitter.
  • LinkedIn.
  • Print

For more news you can use to help guide your financial life, visit our Insights page.


© Reuters 2020. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
close
Please enter a valid e-mail address
Please enter a valid e-mail address
Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.
close

Your e-mail has been sent.

You May Also Like...

A dozen cities for early retirees to think about

Where you choose to retire early can make the difference in whether your savings will stretch over 20, 30 or even 40 years. To help you in your search, we identified 12 cities with potential based on size and cost of living.

Getting the most out of retirement

Looking for retirement planning advice? Answer a series of questions to discover your unique results of highest-rated articles—from saving money and getting the most out of Social Security, to figuring out where to live and how to manage healthcare costs.

Making sense of Medicare coverage options

When you become eligible for Medicare, you'll have an alphabet of coverage options to consider. Learn how to decode the assortment of important choices.